cannabis
- Home
- cannabis
Public
Research Note - Rise of the Cashless Economy
- Review
- June 3, 2020
Novatti launches new payments platform for purpose-issued Visa cards
- Review
- September 29, 2020
Latest Articles
Epsilon Healthcare expands medicinal cannabis telehealth to in-clinic locations
Having developed a thriving telehealth business that has seen significant uptake from patients seeking medicinal cannabis solutions, Epsilon Healthcare (ASX: EPN) is set to expand into retail locations for in-clinic consultations. While the progressive healthcare provider moves in the opposite direction to other medical clinics which were forced to adopt telehealth during the pandemic, telehealth
Read MorePublic
Althea lands first purchase order with WeedMD for cannabis products
Medicinal cannabis and research company Althea Group (ASX: AGH) has today announced that its Canadian subsidiary, Peak Processing, has received a binding purchase order from WeedMD Rx (A subsidiary of canadian listed company WeedMD Inc, TSX-V: WMD). The CAD$130,000 order will see Peak perform a variety of services for WeedMD, including hydrocarbon extraction of fresh-frozen
Read MorePublic
ECS Botanics lines up UK and German customers for cannabis exports
Medicinal cannabis company ECS Botanics (ASX: ECS) is quickly growing its international sales pipeline following their acquisition of Murray Meds last month, securing UK pharmaceuticals company The Armour Group on a 3-year export deal. The agreement will be for the sale, export and distribution of medicinal cannabis products in the UK for clinical trials initially,
Read MorePublic
Ecofibre secures CBD distribution to 5,000 US pharmacies
At a time when medicinal cannabis companies are readying for a boon in Australia brought upon by regulatory easing, hemp products company Ecofibre (ASX: EOF) is set to make a big splash in the United States having secured a distribution deal that will see its cannabidiol products distributed by more than 5,000 pharmacies. The exclusive
Read MorePublic
Emyria to register cannabinoid-based medicine targeting anxiety and depression
Pharmaceuticals company Emyria (ASX: EMD) is set to commence the regulatory process of registering their cannabinoid-based medicine EMD-003 as a treatment to reduce symptoms of mental health disorders, leveraging extensive data gathered from their network of clinics. Initial evidence collected by Emyria’s subsidiary Emerald Clinics has identified an unmet need by targeting the treatment of
Read MorePublic
Cannabis sector flying high following United Nations declassification
In a landmark decision that is tipped to normalise the use of medicinal cannabis, the United Nations has voted to remove cannabis from being a Schedule IV drug, sending the ASX cannabis sector upward in a regulatory move that will encourage individual nations to follow suit. The UN drugs treaty was first introduced in 1961
Read MorePublic